Cantor Fitzgerald analyst Steven Seedhouse reiterated an Overweight rating on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst commented, "In C3G, Empaveli was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE